XML 15 R2.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Current Assets:    
Cash and cash equivalents $ 971,193 $ 608,628
Marketable securities 4,325 4,550
Accounts receivable, net of allowances of $0 and $0 at June 30, 2020 and December 31, 2019, respectively 22,258 295
Inventory 20,807 0
Prepaid expenses 21,105 21,818
Other current assets 3,788 3,413
Total current assets 1,043,476 638,704
Property and equipment, net of accumulated depreciation and amortization of $9,955 and $7,925 at June 30, 2020 and December 31, 2019, respectively 33,512 32,762
Other long-term assets 142 256
Total Assets 1,077,130 671,722
Current Liabilities:    
Accounts payable and accrued expenses 59,862 60,860
Liability related to sale of future royalties - current 21,043 3,455
Lease liability - current 356 337
Convertible senior notes, net 0 7,106
Total current liabilities 81,261 71,758
Liability related to sale of future royalties - non-current 267,650 257,769
Deferred revenues 126,210 65,000
Lease liability - non-current 9,782 9,965
Total Liabilities 484,903 404,492
Commitments and Contingencies (Note 12)
Stockholders' Equity:    
Convertible preferred stock, $0.01 par value; authorized 10,000,000 shares; no shares issued and outstanding at June 30, 2020 and December 31, 2019 0 0
Common stock, $0.01 par value; authorized 275,000,000 shares at June 30, 2020 (250,000,000 at December 31, 2019); issued 231,073,471 shares and outstanding 230,953,850 shares at June 30, 2020; issued 212,529,313 shares and outstanding 212,409,692 shares at December 31, 2019 2,311 2,125
Capital contributed in excess of par 2,063,819 1,579,205
Treasury stock, at cost: 119,621 shares at June 30, 2020 and December 31, 2019 (2,095) (2,095)
Accumulated deficit (1,469,919) (1,310,406)
Accumulated other comprehensive loss (795) (568)
Total Immunomedics, Inc. stockholders' equity 593,321 268,261
Noncontrolling interest in subsidiary (1,094) (1,031)
Total Stockholders' Equity 592,227 267,230
Total Liabilities and Stockholders' Equity $ 1,077,130 $ 671,722